FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term

FDA delays AstraZeneca decision on camizestrant as regulators seek more data

The filing is backed by results from the pivotal SERENA-6 Phase III trial

IIT Madras’s injectable hydrogel could reduce fibrosis treatment cost by 85%

HPS felicitates Padma Shri awardee Dr. G. Venkat Rao for outstanding work in healthcare

The Hyderabad Public School Society celebrates Dr Rao’s journey from HPS Ramanthapur to becoming one of India's leading medical professionals

Supreme Court declares right to trauma care part of Article 21 in landmark judgement

The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors

India’s MedTech industry is entering its defining decade: Dr. Shravan Subramanyam, MD, BPL Medical Technologies

From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies

Eli Lilly secures full PBM coverage for obesity drug portfolio expanding access to millions

The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach

AbbVie wins FDA nod for DECNUPAZ in rare blood cancer

BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes

Hikal swings back to profit in Q4 FY26 despite regulatory hit & strategic charges

Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments